etidronate has been researched along with Kidney Failure, Chronic in 10 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with etidronate, 400 mg daily, induced total regression of severe, disabling periarticular calcifications during a treatment period of 42 months in a patient with chronic kidney disease on dialysis treatment." | 1.36 | [Regression of severe periarticular calcifications during treatment with bisphosphonate in a dialysis patient]. ( Larsen, NA; Obad, D; Pedersen, EB, 2010) |
| "Bisphosphonates may be effective in treating calciphylaxis and arteriosclerosis obliterans by reducing the formation of ectopic calcification around blood vessels." | 1.34 | Intractable wounds caused by calcific uremic arteriolopathy treated with bisphosphonates. ( Hanafusa, T; Katayama, I; Nishimura, Y; Tani, M; Umegaki, N; Yamaguchi, Y, 2007) |
| "Etidronate was well tolerated during the study." | 1.32 | Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. ( Akiba, T; Aoki, T; Majima, K; Nihei, H; Nitta, K; Suzuki, K; Uchida, K; Watanabe, R, 2004) |
| "These appearances are frequently seen in renal osteodystrophy but are uncommon in malignant disease." | 1.26 | Absent kidney sign associated with symmetrical and uniformly increased uptake of radiopharmaceutical by the skeleton. ( Boyle, IT; Fogelman, I; Greig, WR; McKillop, JH, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (30.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Graaf, P | 1 |
| Schicht, IM | 1 |
| Pauwels, EK | 2 |
| Souverijn, JH | 1 |
| de Graeff, J | 1 |
| Obad, D | 1 |
| Larsen, NA | 1 |
| Pedersen, EB | 1 |
| Nitta, K | 1 |
| Akiba, T | 1 |
| Suzuki, K | 1 |
| Uchida, K | 1 |
| Watanabe, R | 1 |
| Majima, K | 1 |
| Aoki, T | 1 |
| Nihei, H | 1 |
| Ariyoshi, T | 1 |
| Eishi, K | 1 |
| Sakamoto, I | 1 |
| Matsukuma, S | 1 |
| Odate, T | 1 |
| Mori, H | 1 |
| Okada, Y | 1 |
| Tanaka, Y | 1 |
| Hanafusa, T | 1 |
| Yamaguchi, Y | 1 |
| Tani, M | 1 |
| Umegaki, N | 1 |
| Nishimura, Y | 1 |
| Katayama, I | 1 |
| Paterson, CR | 1 |
| Feely, J | 1 |
| Plotast, H | 1 |
| Grzegorzewska, AE | 1 |
| Junik, R | 1 |
| Sowinski, J | 1 |
| Gembicki, M | 1 |
| Fogelman, I | 1 |
| McKillop, JH | 1 |
| Boyle, IT | 1 |
| Greig, WR | 1 |
| de Jonge, FA | 1 |
| Hamdy, NA | 1 |
1 review available for etidronate and Kidney Failure, Chronic
| Article | Year |
|---|---|
Scintigraphy in the clinical evaluation of disorders of mineral and skeletal metabolism in renal failure.
Topics: Amyloidosis; Calcinosis; Chronic Kidney Disease-Mineral and Bone Disorder; Etidronic Acid; Humans; K | 1991 |
1 trial available for etidronate and Kidney Failure, Chronic
| Article | Year |
|---|---|
Effect of etidronic acid on arterial calcification in dialysis patients.
Topics: Aged; Aorta, Abdominal; Aorta, Thoracic; Bone Density Conservation Agents; Calcinosis; Coronary Vess | 2006 |
8 other studies available for etidronate and Kidney Failure, Chronic
| Article | Year |
|---|---|
Bone scintigraphy in uremic pulmonary calcification.
Topics: Adolescent; Adult; Bone and Bones; Calcinosis; Etidronic Acid; Female; Humans; Kidney Failure, Chron | 1979 |
[Regression of severe periarticular calcifications during treatment with bisphosphonate in a dialysis patient].
Topics: Bone Density Conservation Agents; Calcinosis; Etidronic Acid; Humans; Kidney Failure, Chronic; Male; | 2010 |
Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis.
Topics: Aged; Blood Chemical Analysis; Bone Density; Coronary Stenosis; Etidronic Acid; Female; Glycoprotein | 2004 |
Etidronate for the treatment of progressive tumoral calcinosis in hemodialysis patients.
Topics: Adult; Bone Density Conservation Agents; Calcinosis; Disease Progression; Etidronic Acid; Humans; Ki | 2007 |
Intractable wounds caused by calcific uremic arteriolopathy treated with bisphosphonates.
Topics: Calciphylaxis; Etidronic Acid; Humans; Kidney Failure, Chronic; Male; Middle Aged; Renal Dialysis; S | 2007 |
Vitamin D metabolites and analogues, diphosphonates, danazol, and bromocriptine.
Topics: Acromegaly; Bromocriptine; Calcitriol; Danazol; Endometriosis; Etidronic Acid; Female; Fibrocystic B | 1983 |
A comparison of bone scans in uremic patients treated with intermittent peritoneal dialysis or hemodialysis.
Topics: Adult; Bone and Bones; Chronic Kidney Disease-Mineral and Bone Disorder; Etidronic Acid; Female; Hum | 1996 |
Absent kidney sign associated with symmetrical and uniformly increased uptake of radiopharmaceutical by the skeleton.
Topics: Adolescent; Adult; Aged; Bone and Bones; Child; Chronic Kidney Disease-Mineral and Bone Disorder; Et | 1977 |